|Day Low/High||1.58 / 1.75|
|52 Wk Low/High||0.21 / 1.57|
Nine biotech and drug companies want FDA approval, but need changed standards to get it.
The firms all have drugs they want the feds to bend the rules to approve.
With a pair of Phase III trials coming up for its dermatological drug, Novan CEO Nate Stasko says the company is merely piercing the skin of its long-term potential.